Bioheart
Latest round
- Series B
Last raised
- Dec 2019
Total raised
- Undisclosed
Investors
- 4
About Bioheart
Established in 2014 and based in Shanghai, China, Bioheart is an innovative interventional cardiovascular company focuses on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. The company has about 3000 square meters, including around 1800 square meters of class 10,000 clean workshops and a full-project testing laboratory for related products. The company has established a quality management system which meets the ISO13485/YY0287 standard. The company has gathered professionals in machinery, polymer, precision processing and clinical medicine with extensive experience in product design, quality control, clinical verification, and market development. In 2013, the company launched R&D of BRS product, and RDN product. In 2014, BRS product received interim reports from animal experiments, which preliminarily prove the safety and effectiveness of the products. In 2015, BRS products obtained product registration type inspection report. In 2019, BRS product completed the 3 years follow-up of the FIM clinical trial. Meanwhile, Iberis multi-electrode RDN system completed FIM clinical trial in Japan. The company's products can be divided BRS products, RDN product, and other products. The BRS products include Bioheart BRS system, Bio-Leap below the knee, Bioheart ultra, and Bio-Leap below the knee, Bioheart ultra both are in animal studies. The RDN product is Iberis generation RDN system, which complete confirmatory clinical trial in China, feasibility clinical tral completed in China, and next step is to initiate confirmatory clinical trial. Other products has been in design stage. The company plans to R&D and commercialization of core product, including confirmatory clinical trial, and registration fillings.
Who invested in Bioheart
4 investors across 2 rounds
See all investors in Bioheart
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bioheart
Who invested in Bioheart?
Bioheart has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bioheart raised?
Bioheart has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Bioheart last raise money?
Bioheart's most recent round on record is a Series B, in Dec 2019.
What does Bioheart do?
Established in 2014 and based in Shanghai, China, Bioheart is an innovative interventional cardiovascular company focuses on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Where is Bioheart headquartered?
Bioheart is headquartered in Shanghai, China.
Which VCs invest in companies like Bioheart?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back medical devices & equipment companies at Bioheart's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Bioheart? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.